ES2196032T3 - Mutantes y vacunas del virus de la anemia infecciosa de los pollos y utilizaciones basadas sobre las proteinas virales vp1, vp2 y vp3 o secuencias de dicho virus que las codifican. - Google Patents

Mutantes y vacunas del virus de la anemia infecciosa de los pollos y utilizaciones basadas sobre las proteinas virales vp1, vp2 y vp3 o secuencias de dicho virus que las codifican.

Info

Publication number
ES2196032T3
ES2196032T3 ES94925638T ES94925638T ES2196032T3 ES 2196032 T3 ES2196032 T3 ES 2196032T3 ES 94925638 T ES94925638 T ES 94925638T ES 94925638 T ES94925638 T ES 94925638T ES 2196032 T3 ES2196032 T3 ES 2196032T3
Authority
ES
Spain
Prior art keywords
cav
vaccines
virus
addition
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94925638T
Other languages
English (en)
Inventor
Mathieu Hubertus Maria Noteborn
Guus Koch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leadd BV
Original Assignee
Leadd BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd BV filed Critical Leadd BV
Application granted granted Critical
Publication of ES2196032T3 publication Critical patent/ES2196032T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/10011Circoviridae
    • C12N2750/10021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/10011Circoviridae
    • C12N2750/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN NUEVAS PROTEINAS DEL VIRUS DE ANEMIA DE POLLO Y COMPOSICIONES PARA PREVENIR O TRATAR INFECCIONES CON ESE VIRUS (CAV), EN PARTICULAR VACUNAS MENOS PATOGENICAS QUE EL PROPIO CAV, AUNQUE TODAVIA CONDUCEN A NEUTRALIZAR ANTICUERPOS EN EL ANIMAL INMUNIZADO. ADEMAS, SE DESCRIBEN COMPOSICIONES QUE CONTIENEN ANTICUERPOS CONTRA PARTES DEL CAV PARA EL CONTROL DE INFECCIONES CON CAV Y ANTICUERPOS ANTI-IDIOTIPO. LA INVENCION TAMBIEN PROPORCIONA ANTICUERPOS Y KITS DE PRUEBA PARA LA DETECCION DE CAV. MEDIANTE ESTA INVENCION, SE HACEN POSIBLES MOLECULAS DE ADN RECOMBINANTE DERIVADAS DE CAV Y CELULAS HUESPED TRASFERIDAS CON LAS MISMAS Y VACUNAS BASADAS EN ESTAS CELULAS HUESPED. LA INVENCION TAMBIEN COMPRENDE VACUNAS DE VIRUS VIVO EN LAS QUE UNA PIEZA DE ADN SE LLEVA A UN VIRUS INFECCIOSO PARA LA CELULA. ADEMAS, LA INVENCION PROPORCIONA USOS DE PROTEINAS DE CAV EN LA INDUCCION DE APOPTOSIS, EN PARTICULAR EN CELULAS TUMORALES. ADEMAS PROPORCIONA LA INDUCCION DE MUERTE CELULAR POR MEDIO DE TERAPIAGENICA.
ES94925638T 1993-07-20 1994-07-19 Mutantes y vacunas del virus de la anemia infecciosa de los pollos y utilizaciones basadas sobre las proteinas virales vp1, vp2 y vp3 o secuencias de dicho virus que las codifican. Expired - Lifetime ES2196032T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9301272A NL9301272A (nl) 1993-07-20 1993-07-20 Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.

Publications (1)

Publication Number Publication Date
ES2196032T3 true ES2196032T3 (es) 2003-12-16

Family

ID=19862681

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94925638T Expired - Lifetime ES2196032T3 (es) 1993-07-20 1994-07-19 Mutantes y vacunas del virus de la anemia infecciosa de los pollos y utilizaciones basadas sobre las proteinas virales vp1, vp2 y vp3 o secuencias de dicho virus que las codifican.
ES01205103T Expired - Lifetime ES2311005T3 (es) 1993-07-20 1994-07-19 Mutantes y vacunas del virus de la anemia infecciosa de los pollos basadas sobre la proteina viral vp3 o secuencias de dicho virus que las codifica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01205103T Expired - Lifetime ES2311005T3 (es) 1993-07-20 1994-07-19 Mutantes y vacunas del virus de la anemia infecciosa de los pollos basadas sobre la proteina viral vp3 o secuencias de dicho virus que las codifica.

Country Status (13)

Country Link
US (1) US5952002A (es)
EP (2) EP1253201B1 (es)
JP (1) JP3829290B2 (es)
AT (2) ATE236980T1 (es)
AU (1) AU703187B2 (es)
CA (1) CA2167578C (es)
DE (2) DE69435117D1 (es)
DK (2) DK0784685T3 (es)
ES (2) ES2196032T3 (es)
NL (1) NL9301272A (es)
PT (2) PT1253201E (es)
WO (1) WO1995003414A2 (es)
ZA (1) ZA945275B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234466A1 (en) * 1990-09-12 2008-09-25 Noteborn Mathieu H M Delivery method for the tumor-specific apoptosis-inducing activity of apoptin
US6162461A (en) * 1990-09-12 2000-12-19 Leadd B.V. Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor
EP0872552A1 (en) * 1997-04-15 1998-10-21 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
US5789567A (en) * 1994-07-06 1998-08-04 Cornell Research Foundation, Inc. Chicken infectious anemia virus vaccine
GB9414888D0 (en) * 1994-07-23 1994-09-14 Univ Belfast Method and composition
ES2200065T3 (es) * 1995-06-07 2004-03-01 Leadd B.V. Utilizacion de apoptina.
JPH11510367A (ja) * 1995-06-07 1999-09-14 アエスキュラープ ビー.ヴィ. ニワトリ貧血ウイルスの中和性立体配座エピトープ
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
US7361730B1 (en) * 1999-03-15 2008-04-22 University Of Maryland Surface localized colligin/Hsp47 in carcinoma cells
EP1199363A1 (en) * 2000-10-20 2002-04-24 Leadd B.V. Phosphorylation modifications of apoptin
AUPR567401A0 (en) * 2001-06-14 2001-07-12 University Of Melbourne, The Circovirus vaccines
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
EP2371382B1 (en) 2005-12-29 2016-03-02 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
CN102311928B (zh) * 2011-08-25 2013-04-24 中国农业科学院哈尔滨兽医研究所 鸡贫血病毒vp1、vp2蛋白共表达的重组酵母工程菌、其构建方法及应用
JP7088835B2 (ja) 2015-10-16 2022-06-21 カンザス ステイト ユニバーシティ リサーチ ファウンデーション ブタサーコウイルス3型免疫原性組成物、その製造方法、およびその使用方法
WO2017187131A1 (en) * 2016-04-26 2017-11-02 London School Of Hygiene & Tropical Medicine Reoviridae vaccine
CN113980146B (zh) * 2021-11-11 2022-09-27 扬州优邦生物药品有限公司 三聚体化鸭黄病毒E蛋白domainIII、其制备方法和运用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) * 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
ZA918426B (en) * 1990-10-31 1992-12-30 Akzo Nv Chicken anemia virus vaccine and diagnostic
ZA927014B (en) * 1991-09-20 1993-03-19 Akzo Nv Chicken anaemia agent vaccine.

Also Published As

Publication number Publication date
WO1995003414A3 (en) 1995-03-02
AU7547394A (en) 1995-02-20
ATE401406T1 (de) 2008-08-15
EP0784685B1 (en) 2003-04-09
JPH09504941A (ja) 1997-05-20
NL9301272A (nl) 1995-02-16
DK0784685T3 (da) 2003-08-04
ATE236980T1 (de) 2003-04-15
DE69432486T2 (de) 2004-03-04
DK1253201T3 (da) 2008-11-17
PT1253201E (pt) 2008-10-27
EP1253201A2 (en) 2002-10-30
EP1253201A3 (en) 2003-01-08
WO1995003414A2 (en) 1995-02-02
EP0784685A2 (en) 1997-07-23
ES2311005T3 (es) 2009-02-01
CA2167578C (en) 2007-03-13
DE69435117D1 (de) 2008-08-28
ZA945275B (en) 1995-02-24
JP3829290B2 (ja) 2006-10-04
EP1253201B1 (en) 2008-07-16
US5952002A (en) 1999-09-14
CA2167578A1 (en) 1995-02-02
AU703187B2 (en) 1999-03-18
PT784685E (pt) 2003-08-29
DE69432486D1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
ES2196032T3 (es) Mutantes y vacunas del virus de la anemia infecciosa de los pollos y utilizaciones basadas sobre las proteinas virales vp1, vp2 y vp3 o secuencias de dicho virus que las codifican.
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
Altomonte et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
CL2020002960A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
CO2021013878A2 (es) Vectores de virus adenoasociado recombinantes
BR9712592A (pt) Processo para gerar um clone infeccioso, ácido nucléico recombinante, molécula do mesmo, vìrus de rna modificado, célula infectada com o mesmo, vacina, proteìna e/ou antìgeno, e, ensaio diagnóstico
ATE474048T1 (de) Her2/neu fusionsproteine
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
ES2145000T3 (es) Virus recombinante del avipox.
CO2021016200A2 (es) Composiciones útiles para el tratamiento de la enfermedad de pompe
Cao et al. Proteomics analysis of differentially expressed proteins in chicken trachea and kidney after infection with the highly virulent and attenuated coronavirus infectious bronchitis virus in vivo
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
Nfon et al. Loss of plasmacytoid dendritic cell function coincides with lymphopenia and viremia during foot-and-mouth disease virus infection
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
ATE349225T1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
Ojima et al. The importance of subfragment 2 and C‐terminus of myosin heavy chain for thick filament assembly in skeletal muscle cells
DK0491824T4 (da) Humane parvovirus B19-proteiner og viruslignende partikler, deres fremstilling og anvendelse til diagnostiske bestemmelser og vacciner
Lyu et al. Deletion of pseudorabies virus US2 gene enhances viral titers in a porcine cerebral cortex primary culture system
EA200301207A1 (ru) Новые экспрессирующие векторы и их применение
AR124385A1 (es) Parapoxvirus modificado que tiene una inmunogenicidad aumentada
ES2074422T3 (es) Moleculas de adn y arn del subtipo accidental del virus fsma, polipeptidos, que son codificados por estas moleculas, y su uso.
BR112022003206A2 (pt) Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte